Global Pulmonary Drug Delivery Market- Industry Trends and Forecast to 2024

  • In Vitro Diagnostics
  • Upcoming Report
  • Sep 2017
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
Global Pulmonary Drug Delivery Market, By Type (Dry Powder Inhalers, Nebulizers, Metered Dose Inhalers, Solution Aerosols, Suspension Aerosols), Application (Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications), End-User (Hospitals & Clinics, Home Care Settings), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-Commerce), Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024

Market Analysis: Global Pulmonary Drug Delivery Market

The global pulmonary drug delivery market accounted to USD 36.50 billion in 2016 growing at a CAGR of 7.0% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Market Definition: Global Pulmonary Drug Delivery Market

Pulmonary drug delivery devices are used since long for the deliveryof drugs for the treatment of respiratory diseases. Pulmonary drug delivery pathway is the most effectivemanner of drug delivery in respiratory diseases as the lungs offer a huge surface area of alveoli with vast higher capillary network which offers an excellent absorbing surface for administration of drugs. Advances in device technology have also led to the expansion of more proficient delivery systems that’s capable of providing large doses and micro particles into the lung.

Major Market Drivers and Restraints:

  • Technological Advancement
  • Growing Incidence of Respiratory Diseases
  • Rising Focus on the Expansion of Smart/Digital Inhalers
  • Regulatory Concerns
  • Stability Issues With The Products

Market Segmentation: Global Pulmonary Drug Delivery Market

By type the global pulmonary drug delivery market is segmented intodry powder inhalers, nebulizers, metered dose inhalers, solution aerosols, and suspension aerosols.

On the basis ofapplicationthe global pulmonary drug delivery market is segmented intochronic obstructive pulmonary disease, asthma, cystic fibrosis, and other applications.

On the basis of end-user the global pulmonary drug delivery market is segmented into hospitals & clinics, and home care settings.

Based on the distribution channel the global pulmonary drug delivery market is segmented intoretail pharmacies, hospital pharmacies, and E-commerce.

On the basis of geography, global pulmonary drug delivery market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.

Competitive Analysis: Global Pulmonary Drug Delivery Market

The global pulmonary drug delivery market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of pulmonary drug delivery market for global, Europe, North America, Asia Pacific and South America.

Major Market Competitors: Global Pulmonary Drug Delivery Market

Some of the major players operating in global pulmonary drug delivery market areGlaxoSmithKline plc, 3M, AstraZeneca, Boehringer Ingelheim GmbH, Koninklijke Philips N.V., PARI, GF Health Products Inc., Merck & Co., Inc., Progressive Trade Media Limited, BeyonDevices, Lda, Aphios, AptarGroup, Inc., Novartis AG, F. Hoffmann-La Roche Ltd.,TTP plc,Hovione,Teva Pharmaceutical Industries Ltd., OMRON Corporation, Catalent, Inc. and Sunovion Pharmaceuticals Inc.among others

Research Methodology: Global Pulmonary Drug Delivery Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or drop down your enquiry.

Demand Side Primary Contributors: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART